Search PubMed⌕ Search

Biomedical subjects

D Vitali

Publications and source records attributed to D Vitali.

36 records · Page 2Linked to original sources
PubMed1985

Use of the YAG laser with a seven-micron spot in pseudophakic eyes.

We report on 216 cases of posterior capsulotomy performed with a LASAG Microruptor II YAG laser in patients with posterior chamber intraocular lenses. In 108 cases, the YAG laser was used in multimode with a 70-micron spot and 3.5 mJ to 5.0 mJ of energy; in the other 108 cases, the laser was used in fundamental mode with a 7-micron spot and 0.7 mJ to 1.2 mJ of energy. In the first group, IOL damage was seen in 10.2% of cases, uveitis developed in 0.4% of patients, and transient eye pressure elevation was noted in 6.5% of patients. In the second group, neither IOL damage nor uveitis occurred, and only two cases (1.8%) developed transient pressure elevation.

Aged↗
PubMed1979

Treatment of fulminant viral hepatitis with anti-lymphocyte gamma globulins.

Ten patients affected by fulminant viral hepatitis (F.V.H.) were treated with anti-lymphocyte globulins (A.L.G.) besides peritoneal dialysis (P.D.) and exchange blood transfusion (E.T.). Two patients awoke transiently; six recovered from F.V.H., but two of them died afterwards due to later complications. The total of complete recovery was 40%; this result is compared with those previously obtained by the Authors in 38 patients treated only with P.D. and E.T. (28.9% complete recovery), and in seven patients treated with P.D., E.T. and human anti-HBsAg gamma globulins (28.5% complete recovery). The treatment with A.L.G. was performed because of the discouraging results until now obtained with the various liver support systems and is based on the accepted view that lymphocytes might be the true effectors of cell necrosis in F.V.H.

Acute Disease↗
PubMed1978

[Use of an immunomodulator (levamisole) in HbsAg positive patients].

The results of some clinical trials performed with levamisole on 12 HBsAg-positive subjects, including 5 patients with aggressive chronic hepatitis, (ACH) 2 patients with persistent chronic hepatitis (PCH) and 5 healthy carriers are reported. Levamisole was administered in 2.5 mg/Kg/day doses for three consecutive days. During treatment prothrombin activity normalized in ACH and PCH as well as transaminases, the latter starting from the 4th week, even though a two-fourfold increase of the starting values was observed in the first weeks of disease. HBsAg, anti-HBs titres and immunocomplexes values did not show any significant variations, but for 1 case, while some immunological parameters (E, EA rosettes) normalized in those cases showing base- values lower than the norm.

Adult↗
PubMedDate not supplied

Occupancy by oral administration of nicardipine of L-type calcium channels in rat brain.

The occupancy of L-type Ca2+ channels by treatment with an oral dose of the dihydropyridine-type Ca2+ antagonist nicardipine (sustained-release formulation) was evaluated in membrane preparations of rat frontal cortex and hippocampus using a radioligand binding assay technique, with [3H]-nicardipine as a ligand. Three hours after nicardipine administration, specific binding was decreased by about 15-20%, both in the frontal cortex and hippocampus. This indicates that oral nicardipine occupied approximately 15-20% of L-type Ca2+ channels. A progressive occupancy of Ca2+ channels was observed between six and 12 h after nicardipine administration. Twelve hours after drug administration, approximately 65-70% of Ca2+ channels were occupied. These findings indicate that oral treatment with 3 mg/kg of nicardipine (sustained-release formulation) occupies L-type Ca2+ channels in rat brain by more than 40% from the 6th to the 24th h after drug administration. This suggests that an oral dose of nicardipine (sustained-release formulation) in duces a significant occupancy of L-type Ca2+ channels in rat frontal cortex and hippocampus for about one day. The possible clinico-therapeutic relevance of this observation is discussed.

Administration, Oral↗
PubMedDate not supplied

Effects of a methanolic extract and a hyperforin-enriched CO2 extract of Hypericum perforatum on alcohol intake in rats.

Hypericum perforatum extracts (HPE) inhibit ethanol intake in rats. Hypericin and hyperforin have been proposed as major active principles of HPE. The present study compared the effect on ethanol intake in alcohol-preferring rats of two Hypericum perforatum extracts: a methanolic extract containing 0.3% hypericin and 3.8% hyperforin (HPE1) and a CO2 extract (HPE2) with 24.33% hyperforin and very low hypericin content. Freely feeding and drinking rats were offered 10% ethanol 2 h/day and HPE were given intragastrically 1 h before access to ethanol. Both extracts dose-dependently reduced ethanol intake, HPE2 being about eight times more potent than HPE1. Food and water intakes were not affected by doses that reduced ethanol intake. HPE2, unlike HPE1, reduced blood-alcohol levels (BAL) at doses of > or = 31.2 mg/kg, whereas the dose of 15.6 mg/kg, which reduced ethanol intake, did not significantly modify BAL; blood-acetaldehyde levels were never increased. As previously observed for HPE1, intracerebroventricular pretreatment with 5,7-dihydroxytryptamine (150 microg/rat) did not affect attenuation of ethanol intake induced by HPE2, but reduced its effect in the forced swimming test (FST). Intraperitoneal pretreatment with the sigma-1 receptor antagonist NE-100 (0.25 mg/kg) did not affect inhibition of ethanol intake induced by HPE1 (250 mg/kg) or HPE2 (125 mg/kg), but abolished the effect of both extracts in the FST. In conclusion, the present results indicate that HPE2 inhibits ethanol intake more potently than HPE1; the higher potency of HPE2 parallels the hyperforin content, suggesting that hyperforin may have an important role in reducing ethanol intake. Moreover, different neurochemical mechanisms are apparently responsible for the reduction of ethanol intake and for the antidepressant-like effect of HPE.

5,7-Dihydroxytryptamine↗